Johanna Rodríguez: The Structural Challenge of Next-Gen Anticoagulants
Johanna Rodríguez, Translational Scientist – Protein Therapeutics and Project Coordination, shared a post on LinkedIn:
“The Structural Challenge of Next-Gen Anticoagulants
For a long time, developing anticoagulants has meant accepting a direct dilemma: if you stop a pathological clot, you inevitably increase the patient’s risk of bleeding.
That is why the structural biology behind Factor XIa is so compelling. Looking at this crystal structure (PDB: 8BO5), you can see the symmetrical homodimer architecture with both catalytic domain pockets highlighted in gold.
Modern drug design targets these specific active site clefts to decouple thrombosis from hemostasis entirely.
By targeting these binding pockets, the goal is to aggressively shut down the contact-activated amplification loop that drives dangerous clots, while leaving the body’s natural, early bleeding control completely intact.
But beautiful 3D models are just the starting point for translational teams. To validate a target and select a clinical dose, you need solid functional data testing on how these dynamics play out in primary human cell assays, platelet activation, and real-time clot composition.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 13:29Factor XI Deficiency and the Challenge of Unpredictable Bleeding – EHC
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios Andreadis։ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI